ORYZON holds its 4th annual Solidarity Day
MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, October 20th, 2020 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, celebrated yesterday the Oryzon Solidarity Day (OSD) for the fourth consecutive year. The OSD is an annual initiative whereby the company's employees devote part of their working hours to carry out activities that can have a positive impact on society.
The COVID 19 pandemic has had a strong impact on social relations, economic activity and the health of the world's population. Blood reserves have been made available to health centers, and the degree of demand has generated a deficit situation for blood transfusions. Collaboration and social contribution are especially necessary at these difficult times. Within the framework of its annual OSD 2020, Oryzon has promoted a collaboration with the Vall d'Hebron hospital that has allowed the donation of blood by Oryzon’s employees, contributing to the supply of the hospital’s blood bank.
Enric Rello, Oryzon’s CFO & COO and CSR Director, commented: “Donating blood is a right and a moral obligation for all of us who can collaborate with our society. But there are many other disadvantaged people who have further needs as a consequence of the economic crisis derived from the COVID 19 pandemic, in particular access to food. For this reason, for each blood donation made by our employees during the OSD the company will contribute with money to the food campaign coordinated by the Red Cross of Cornellà de Llobregat.”
Additionally, during OSD 2020 actions have been carried out to disseminate and promote bone marrow donation, promoting the incorporation of donors in the Spanish Registry of Bone Marrow Donors (REDMO). Bone marrow transplantation is a medical procedure to replace defective stem cells in the bone marrow of a person with leukemia or other blood diseases.
Oryzon currently has a drug under clinical development in the field of leukemia, iadademstat, which is being evaluated in a Phase II clinical trial in first-line elderly patients with acute myeloid leukemia not eligible for intensive chemotherapy, in combination with the hypomethylating agent azacitidine (ALICE trial). Oryzon has published promising preliminary efficacy results at several international conferences, most recently at the European Association of Hematology (EHA) conference, EHA-2020, and expects to present additional data from this trial at the American Society of Hematology conference, ASH-2020, in December.
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds, vafidemstat and iadademstat, in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has offices in Spain and the United States. For more information, visit www.oryzon.com
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzon’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzon’s securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.